Neurotherapeutics,
Год журнала:
2015,
Номер
12(4), С. 735 - 746
Опубликована: Авг. 12, 2015
There
is
extensive
research
on
the
safety,
toxicology,
potency,
and
therapeutic
potential
of
cannabis.
However,
uncertainty
remains
facilitating
continued
debate
medical
recreational
cannabis
policies
at
state
federal
levels.
This
review
will
include
a
brief
description
cannabinoids
endocannabinoid
system;
summary
acute
long-term
effects
cannabis;
discussion
The
conclusions
about
safety
efficacy
then
be
compared
with
current
social
political
climate
to
suggest
future
policy
directions
general
guidelines.
Molecular Pharmacology,
Год журнала:
2014,
Номер
86(4), С. 430 - 437
Опубликована: Авг. 9, 2014
The
past
decades
have
seen
an
exponential
rise
in
our
understanding
of
the
endocannabinoid
system,
comprising
CB1
and
CB2
cannabinoid
receptors,
endogenous
cannabinoids
(endocannabinoids),
enzymes
that
synthesize
degrade
endocannabinoids.
primary
focus
this
review
is
receptor.
receptors
been
subject
considerable
attention,
primarily
due
to
their
promising
therapeutic
potential
for
treating
various
pathologies
while
avoiding
adverse
psychotropic
effects
can
accompany
receptor–based
therapies.
With
appreciation
CB2-selective
ligands
show
marked
functional
selectivity,
there
a
renewed
opportunity
explore
area
research
from
both
mechanistic
as
well
perspective.
In
review,
we
summarize
present
knowledge
receptor
signaling,
localization,
regulation.
We
discuss
availability
genetic
tools
(and
limitations)
study
also
provide
update
on
preclinical
data
agonists
pain
models.
Finally,
suggest
possible
reasons
failure
clinical
trials
offer
ways
move
field
forward
way
help
reconcile
inconsistencies
between
data.
Clinical Journal of Pain,
Год журнала:
2016,
Номер
32(12), С. 1036 - 1043
Опубликована: Фев. 18, 2016
Objectives:
The
objective
of
this
prospective,
open-label
study
was
to
determine
the
long-term
effect
medicinal
cannabis
treatment
on
pain
and
functional
outcomes
in
participants
with
treatment-resistant
chronic
pain.
Patients
Methods:
primary
outcome
change
symptom
score
S-TOPS
(Treatment
Outcomes
Pain
Survey—Short
Form)
questionnaire
at
6-month
follow-up
an
intent-to-treat
population.
Secondary
included
physical,
social,
emotional
disability
scales,
severity,
interference
Brief
Inventory,
sleep
problems,
opioid
consumption.
Results:
A
total
274
were
approved
for
treatment;
complete
baseline
data
available
206
(intent-to-treat),
176
participants.
At
follow-up,
improved
from
median
83.3
(95%
confidence
interval
[CI],
79.2-87.5)
75.0
CI,
70.8-79.2)
(
P
<0.001).
severity
(7.50
[95%
6.75-7.75]
6.25
5.75-6.75])
(8.14
7.28-8.43]
6.71
6.14-7.14])
(both
<0.001),
together
most
social
scores.
Opioid
consumption
decreased
by
44%
Serious
adverse
effects
led
discontinuation
2
Discussion:
open-label,
prospective
cohort
resulted
outcomes,
a
significant
reduction
use.
Results
suggest
benefit
group
patients,
but
study’s
noncontrolled
nature
should
be
considered
when
extrapolating
results.
Headache The Journal of Head and Face Pain,
Год журнала:
2018,
Номер
58(7), С. 1139 - 1186
Опубликована: Июль 1, 2018
Background
Comprehensive
literature
reviews
of
historical
perspectives
and
evidence
supporting
cannabis/cannabinoids
in
the
treatment
pain,
including
migraine
headache,
with
associated
neurobiological
mechanisms
pain
modulation
have
been
well
described.
Most
existing
reports
on
cannabinoids
Δ
9
‐tetrahydrocannabinol
(THC)
cannabidiol
(CBD),
or
cannabis
general.
There
are
many
strains
that
vary
widely
composition
cannabinoids,
terpenes,
flavonoids,
other
compounds.
These
components
work
synergistically
to
produce
wide
variations
benefits,
side
effects,
strain
characteristics.
Knowledge
individual
medicinal
properties
flavonoids
is
necessary
cross‐breed
obtain
optimal
standardized
synergistic
compositions.
This
will
enable
targeting
symptoms
and/or
diseases,
migraine,
pain.
Objective
Review
medical
for
use
facial
chronic
syndromes,
a
potential
role
combatting
opioid
epidemic.
involving
major
minor
primary
secondary
underlie
entourage
effects
cannabis.
Summarize
benefits
these
substances,
analgesic
anti‐inflammatory
properties.
Conclusion
accumulating
various
therapeutic
cannabis/cannabinoids,
especially
which
may
also
apply
headache.
assist
detoxification
weaning,
thus
making
it
weapon
battling
Cannabis
science
rapidly
evolving
sector
industry
increasingly
regulated
production
standards.
Further
research
anticipated
optimize
breeding
strain‐specific
ratios
phytochemicals
predictable
user
characteristics,
improved
symptom
disease‐targeted
therapies.
Mayo Clinic Proceedings,
Год журнала:
2019,
Номер
94(9), С. 1840 - 1851
Опубликована: Авг. 22, 2019
Cannabidiol
(CBD)
oils
are
low
tetrahydrocannabinol
products
derived
from
Cannabis
sativa
that
have
become
very
popular
over
the
past
few
years.
Patients
report
relief
for
a
variety
of
conditions,
particularly
pain,
without
intoxicating
adverse
effects
medical
marijuana.
In
June
2018,
first
CBD-based
drug,
Epidiolex,
was
approved
by
US
Food
and
Drug
Administration
treatment
rare,
severe
epilepsy,
further
putting
spotlight
on
CBD
hemp
oils.
There
is
growing
body
preclinical
clinical
evidence
to
support
use
many
suggesting
its
potential
role
as
another
option
treating
challenging
chronic
pain
or
opioid
addiction.
Care
must
be
taken
when
directing
patients
toward
because
there
little
regulation,
studies
found
inaccurate
labeling
quantities.
This
article
provides
an
overview
scientific
work
cannabinoids,
CBD,
oil
distinction
between
marijuana,
hemp,
different
components
products.
We
summarize
current
legal
status
in
United
States
provide
guide
identifying
higher-quality
so
clinicians
can
advise
their
safest
most
evidence-based
formulations.
review
based
PubMed
search
using
terms
cannabidiol,
oil,
Articles
were
screened
relevance,
those
with
up-to-date
information
selected
inclusion.
Clinical Pharmacology & Therapeutics,
Год журнала:
2015,
Номер
97(6), С. 575 - 586
Опубликована: Март 17, 2015
Cannabis
has
been
used
in
medicine
for
thousands
of
years
prior
to
achieving
its
current
illicit
substance
status.
Cannabinoids,
the
active
components
sativa
,
mimic
effects
endogenous
cannabinoids
(endocannabinoids),
activating
specific
cannabinoid
receptors,
particularly
CB1
found
predominantly
central
nervous
system
and
CB2
cells
involved
with
immune
function.
Delta‐9‐tetrahydrocannabinol,
main
bioactive
plant,
available
as
a
prescription
medication
approved
treatment
cancer
chemotherapy‐induced
nausea
vomiting
anorexia
associated
AIDS
wasting
syndrome.
Cannabinoids
may
be
benefit
cancer‐related
pain,
possibly
synergistic
opioid
analgesics.
have
shown
HIV‐related
peripheral
neuropathy,
suggesting
that
they
worthy
study
patients
other
neuropathic
symptoms.
favorable
drug
safety
profile,
but
their
medical
use
is
limited
by
psychoactive
bioavailability.
